Strong hint towards Amgen licensing a bisantrene+carfilzomib coformulation (that we hold the patent for) here. I love it.
More and more I see the pieces coming together for a series of license-based transactions and partnerships by cancer indication. Cash, royalties, biobux, then a major transaction down the line.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.010(0.86%) |
Mkt cap ! $204.1M | |||
| Open | High | Low | Value | Volume |
| $1.19 | $1.19 | $1.17 | $19.63K | 16.71K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 810 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 2188 | 1 |
View Market Depth
| Last trade - 15.52pm 11/07/2025 (20 minute delay) ? |
| RAC (ASX) Chart |